KORU Medical reports 22% FY2025 revenue growth; positive adjusted EBITDA; initiates FY2026 guidance

KORU Medical Systems, Inc.

Q4 2025 net revenue $10.9M (+23% YoY); FY2025 net revenue $41.1M (+22% YoY).
International Core revenue grew 80% in FY2025; Domestic Core grew 11%.
FY2025 net loss narrowed 57% to $2.6M ($0.06 loss per share); positive adjusted EBITDA of $0.6M.
Cash and cash equivalents $8.9M at Dec 31, 2025; used only $0.7M cash in FY2025.
FY2026 guidance: net revenue $47.5–$50.0M (15–22% growth); positive adjusted EBITDA and positive cash flow.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.